DDInter1867 DDInter1352
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Castor oil
Castor oil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Ethopropazine {u} (Compound) resembles {v} (Compound) Trimipramine
Trimipramine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may lead to a major life threatening interaction when taken with Osimertinib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Triflupromazine (Compound) resembles Promazine (Compound) and Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may lead to a major life threatening interaction when taken with Osimertinib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Triflupromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Triflupromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may lead to a major life threatening interaction when taken with Osimertinib
Triflupromazine (Compound) resembles Ethopropazine (Compound) and Ethopropazine (Compound) resembles Trimipramine (Compound) and Trimipramine may lead to a major life threatening interaction when taken with Osimertinib
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib